Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting drug it has developed to create a new standard of patient care for weight ...

Eli Lilly & Co. increased sales of the weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement ...

Eli Lilly (LLY) increased its sale of Mounjaro, its weight-loss and diabetes drug, by 60% in India in May from April, Satviki Sanjay of Bloomberg ...